COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Cather Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
Catheter Precision, Inc., a US-based medical device company, announces that its CEO and Chairman, Mr. David Jenkins, has been authorized to purchase up to 500,000 shares of the Company's common stock. Mr. Jenkins expresses confidence in the Company's future and its innovative technology for electrophysiology procedures to improve the treatment of cardiac arrhythmias. The press release highlights the Company's focus on developing groundbreaking technology and its achievements with the FDA-registered LockeT product and VIVO 3D mapping system. The press release also contains a cautionary note regarding forward-looking statements and contact information for media inquiries. -
COMMUNIQUÉ DE PRESSE
CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results
Catheter Precision, Inc. (VTAK:NYSE/American), a US-based medical device company, announced unaudited preliminary annual and fourth quarter results of 2023. These results included total revenues, cash on hand, total assets, shareholders equity, and preliminary net loss. The company also highlighted key achievements of the year, including sales and clinical personnel onboarding and training, product launches, study enrollments, and intellectual property expansion. CEO David Jenkins expressed optimism for 2024, emphasizing the momentum and market potential of their products. The company cautioned that the results are subject to finalization, internal review, potential adjustments, and external audit, with consideration for potential impact from impairment analysis and future royalties. For more information, please refer to the original press release on accesswire.com. -
COMMUNIQUÉ DE PRESSE
Catheter Precision, Inc. (VTAK) Announces Changes to Executive Management and Board of Directors
Catheter Precision, a US-based medical device company, has announced changes to its executive management and board of directors, including the appointment of Margrit Thomassen as the interim Chief Financial Officer and the naming of David Jenkins as the Chief Executive Officer. The company, focused on electrophysiology products, aims to continue its growth and meet the needs of patients, hospitals, and physicians. The announcement also includes the resignation of Susanne Meline from the Board of Directors and the appointment of John Francis as her replacement. These changes are part of the company's strategic plan for the upcoming year. -
COMMUNIQUÉ DE PRESSE
Catheter Precision, Inc. (VTAK) Receives Additional Patents for LockeT in Great Britain and the European Market
Catheter Precision, Inc. announced the allowance of two new patents (No. 6288592 and No. 015023977-0001) in Great Britain and the European Market for its LockeT product line, further solidifying the company's IP position. These patents demonstrate the company's commitment to the uniqueness of the closure product design, strengthening its global presence in the electrophysiology products market. -
-
-
COMMUNIQUÉ DE PRESSE
Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Emerging Growth Conference on December 6, 2023
Catheter Precision, Inc. (NYSE American:VTAK) to present its innovative non-invasive 3D mapping system, VIVO, at the Emerging Growth Conference on December 6, 2023. The event offers an opportunity for real-time interaction with the CEO -
-
COMMUNIQUÉ DE PRESSE
Catheter Precision’s VIVO is Now Eligible for National Reimbursement in the UK
